ATE198271T1 - Syndecan-stimulierung der zellulären differenzierung - Google Patents

Syndecan-stimulierung der zellulären differenzierung

Info

Publication number
ATE198271T1
ATE198271T1 AT94900846T AT94900846T ATE198271T1 AT E198271 T1 ATE198271 T1 AT E198271T1 AT 94900846 T AT94900846 T AT 94900846T AT 94900846 T AT94900846 T AT 94900846T AT E198271 T1 ATE198271 T1 AT E198271T1
Authority
AT
Austria
Prior art keywords
syndecan
methods
cellular differentiation
stimulation
cell
Prior art date
Application number
AT94900846T
Other languages
English (en)
Inventor
Anni Maija Waerri
Leena Maria Alanen-Kurki
Petri Olli Viljami Auvinen
Panu Mikko Jaakola
Markku Tapani Jalkanen
Sirpa Marianne Leppae
Markku Sakari Mali
Tapani Antero Vihinen
Original Assignee
Biotie Therapies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25534102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE198271(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biotie Therapies Oy filed Critical Biotie Therapies Oy
Application granted granted Critical
Publication of ATE198271T1 publication Critical patent/ATE198271T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94900846T 1992-12-01 1993-12-01 Syndecan-stimulierung der zellulären differenzierung ATE198271T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98842792A 1992-12-01 1992-12-01
PCT/FI1993/000514 WO1994012162A1 (en) 1992-12-01 1993-12-01 Syndecan stimulation of cellular differentiation

Publications (1)

Publication Number Publication Date
ATE198271T1 true ATE198271T1 (de) 2001-01-15

Family

ID=25534102

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94900846T ATE198271T1 (de) 1992-12-01 1993-12-01 Syndecan-stimulierung der zellulären differenzierung

Country Status (9)

Country Link
EP (1) EP0671909B1 (de)
JP (1) JPH08503848A (de)
AT (1) ATE198271T1 (de)
AU (1) AU687767B2 (de)
CA (1) CA2150714C (de)
DE (1) DE69329802T2 (de)
DK (1) DK0671909T3 (de)
ES (1) ES2154290T3 (de)
WO (1) WO1994012162A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726058A (en) * 1992-12-01 1998-03-10 Jalkanen; Markku Syndecan stimulation of cellular differentiation
US6492344B1 (en) 1993-12-01 2002-12-10 Biotie Therapies Corp. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6017727A (en) * 1994-03-07 2000-01-25 Biotie Therapies Ltd. Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
SI1003496T1 (en) 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413535B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU2003203589B2 (en) * 1998-05-07 2005-10-27 The University Of Tennessee Research Corporation A method for chemoprevention of prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8806893D0 (en) * 1988-03-23 1988-04-27 Unilever Plc Cosmetic composition
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
RU2139540C1 (ru) * 1991-01-15 1999-10-10 Биоти Терапис Лтд. Способ обнаружения озлокачествления

Also Published As

Publication number Publication date
CA2150714C (en) 2002-02-05
AU5564994A (en) 1994-06-22
ES2154290T3 (es) 2001-04-01
AU687767B2 (en) 1998-03-05
EP0671909B1 (de) 2000-12-27
EP0671909A1 (de) 1995-09-20
CA2150714A1 (en) 1994-06-09
WO1994012162A1 (en) 1994-06-09
JPH08503848A (ja) 1996-04-30
DE69329802D1 (de) 2001-02-01
DE69329802T2 (de) 2001-07-19
DK0671909T3 (da) 2001-03-19

Similar Documents

Publication Publication Date Title
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
ATE236921T1 (de) L-ribavirin und dessen verwendung
DE3883374D1 (de) Acylatiertes uridin und cytidin und deren verwendungen.
DE69738615D1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
DE69533581D1 (de) Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
NZ505011A (en) Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
DE69938871D1 (de) Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
ATE227717T1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
EP0151989A3 (en) Means for the treatment of cardiac diseases
ATE212351T1 (de) Androsten-derivate
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
NZ301645A (en) (R)-(-)-methyl phenyl oxazolidinone derivatives, pharmaceutical preparations and use for treating TNF stimulated diseases
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE34077T1 (de) Hautbehandlungsmittel.
ATE198271T1 (de) Syndecan-stimulierung der zellulären differenzierung
ATE217514T1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DE69535081D1 (de) Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
NO994330D0 (no) Metode for behandling av en tumor
DK0637306T3 (da) 4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee